Intronic branchpoint-to-acceptor variants underlying inborn errors of immunity

内含子分支点至受体变异是先天性免疫缺陷的根本原因

阅读:2
作者:Najiba Alioua,Nathalie Lambert,Mathilde Puel,Sylvain Hanein,Paul Bastard ,Mathieu Fusaro,Marie Jaffray,Bernardita Medel,Lydia Khellaf,Yoann Seeleuthner,Mélodie Perin,Corinne Jacques,Marlène Pasquet,Laura Olivier,Fernando Sepulveda,Tom Le Voyer ,Aurélie Cobat ,Patrick Nitschké,Lionel Galicier,Nicolas Schleinitz,Eric Oksenhendler,Marion Malphettes,Bénédicte Neven,Despina Moshous,Felipe Suarez,Claire Fieschi,Jean-Laurent Casanova ,Geneviève de Saint Basile,Guillaume Dorval,Capucine Picard ,Jacinta Bustamante ,Peng Zhang ,Jérémie Rosain

Abstract

Clinical laboratories searching for pathogenic variants focus mostly on the protein-coding region and corresponding essential splicing sites. Screening for variants in intronic regions requires dedicated bioinformatics tools and detailed experimental studies to confirm deleteriousness and pathogenicity. We report intronic variants in a cohort of eight patients from seven kindreds with unexplained inborn errors of immunity (IEI). Using ad hoc bioinformatics tools, we identified seven kindreds carrying three branchpoint variants at three loci (BTK, SH2D1A, and WAS) and four AG-gain acceptor site variants at another three loci (DOCK8, NFKB1, STXBP2, and UNC13D). The variants were located between positions -9 and -49 relative to the wild-type acceptor site. The deleteriousness and, thus, pathogenicity of these variants were confirmed by exon-captured transcriptome studies and flow cytometry analyses of protein production or function. Our findings indicate that intronic variants should be systematically screened and investigated, even in clinical laboratory settings.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。